Related Experiment Video
Updated: Dec 28, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
An atlas of transposable element-derived alternative splicing in cancer
Evan A Clayton1, Lavanya Rishishwar2,3,4, Tzu-Chuan Huang2
1Integrated Cancer Research Center, School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
Abstract:
Transposable element (TE)-derived sequences comprise more than half of the human genome, and their presence has been documented to alter gene expression in a number of different ways, including the generation of alternatively spliced transcript isoforms. Alternative splicing has been associated with tumorigenesis for a number of different cancers. The objective of this study was to broadly characterize the role of human TEs in generating alternatively spliced transcript isoforms in cancer. To do so, we screened for the presence of TE-derived sequences co-located with alternative splice sites that are differentially used in normal versus cancer tissues. We analysed a comprehensive set of alternative splice variants characterized for 614 matched normal-tumour tissue pairs across 13 cancer types, resulting in the discovery of 4820 TE-generated alternative splice events distributed among 723 cancer-associated genes. Short interspersed nuclear elements (Alu) and long interspersed nuclear elements (L1) were found to contribute the majority of TE-generated alternative splice sites in cancer genes. A number of cancer-associated genes, including MYH11, WHSC1 and CANT1, were shown to have overexpressed TE-derived isoforms across a range of cancer types. TE-derived isoforms were also linked to cancer-specific fusion transcripts, suggesting a novel mechanism for the generation of transcriptome diversity via trans-splicing mediated by dispersed TE repeats. This article is part of a discussion meeting issue 'Crossroads between transposons and gene regulation'.
Insights
Transposable elements (TEs) significantly contribute to alternative splicing in cancer, generating thousands of new splice variants in hundreds of genes. These TE-derived isoforms are linked to cancer development and novel fusion transcripts.
Area of Science:
- Genomics
- Molecular Biology
- Cancer Research
Background:
- Transposable elements (TEs) constitute over half of the human genome.
- TEs influence gene expression, including alternative splicing, which is implicated in cancer.
Purpose of the Study:
- To broadly investigate the role of human TEs in generating alternatively spliced transcript isoforms in cancer.
- To screen for TE-derived sequences at differentially used alternative splice sites in normal versus cancer tissues.
Main Methods:
- Analysis of alternative splice variants from 614 matched normal-tumour tissue pairs across 13 cancer types.
- Screening for TE sequences co-located with alternative splice sites.
- Identification and characterization of TE-generated alternative splice events.
Main Results:
- Discovery of 4820 TE-generated alternative splice events in 723 cancer-associated genes.
- Short interspersed nuclear elements (Alu) and long interspersed nuclear elements (L1) were major contributors.
- Overexpression of TE-derived isoforms in genes like MYH11, WHSC1, and CANT1 was observed across various cancers.
Conclusions:
- Human TEs play a substantial role in generating alternative splicing in cancer.
- TEs contribute to transcriptome diversity and potentially drive tumorigenesis through novel splice variants and fusion transcripts.
- TE-mediated trans-splicing represents a novel mechanism for generating transcriptome diversity in cancer.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
RNA Splicing
Overview of Transposition and Recombination
Non-LTR Retrotransposons
DNA-only Transposons
The donor site from where the transposon is excised is either degraded or...

